Fujifilm Kyowa Kirin Biologics granted Mylan an exclusive licence to commercialise its version of adalimumab, Hulio, in Europe. Amgen, Biogen and Samsung Bioepis have all have been granted ...

Story Feb. 4 - Kyowa Kirin: The Japanese pharma is letting go ... shrinking its head count by 40% and reassessing the future of Amgen-partnered T-cell engager CX-904 as a way to save cash and ...

The Japanese pharmaceutical company Kyowa Kirin Co. plans to sell shares in the Chinese division of the Hong Kong company WinHealth Pharma Group Co. for 15 billion yen ($100 million) as part of the ...

Mitsuo Satoh, head of Kyowa Hakko Kirin’s R&D division, said: “As we seek to fulfill our business vision to bring innovative treatments to patients faster, we very much expect that InveniAI ...

The case had been filed last year by Amgen after the state Prescription Drug Affordability Board determined that its big-selling medication called Enbrel is unaffordable and began a process to ...

Based on Wall Street analyst estimates for 2025 EPS, Amgen trades at 15 times its projected earnings, while Merck sits at a forward P/E of 10. By this measure, Merck is the cheaper stock and a ...

We sell different types of products and services to both investment professionals and individual investors. These products and services are usually sold through license agreements or subscriptions ...

Copyright © 2025 MarketWatch, Inc. All rights reserved.